4.74
+0.24(+5.33%)
Currency In USD
| Previous Close | 4.5 |
| Open | 4.49 |
| Day High | 4.77 |
| Day Low | 4.41 |
| 52-Week High | 5.1 |
| 52-Week Low | 2.71 |
| Volume | 1M |
| Average Volume | 1.15M |
| Market Cap | 910.95M |
| PE | -19.75 |
| EPS | -0.24 |
| Moving Average 50 Days | 4.57 |
| Moving Average 200 Days | 3.86 |
| Change | 0.24 |
If you invested $1000 in Arbutus Biopharma Corporation (ABUS) 10 years ago, it would be worth $1,244.09 as of January 14, 2026 at a share price of $4.74. Whereas If you bought $1000 worth of Arbutus Biopharma Corporation (ABUS) shares 5 years ago, it would be worth $1,176.18 as of January 14, 2026 at a share price of $4.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
GlobeNewswire Inc.
Oct 07, 2025 12:00 PM GMT
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
GlobeNewswire Inc.
Jun 25, 2025 11:30 AM GMT
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
GlobeNewswire Inc.
May 07, 2025 6:01 AM GMT
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibit